Undiscovered Gems in Europe with Strong Fundamentals July 2025
Name
Debt To Equity
Revenue Growth
Earnings Growth
Health Rating
La Forestière Equatoriale
NA
-65.30%
37.55%
★★★★★★
Linc
NA
101.28%
29.81%
★★★★★★
Caisse Regionale de Credit Agricole Mutuel Toulouse 31
19.46%
0.47%
7.14%
★★★★★☆
Decora
18.47%
11.59%
10.86%
★★★★★☆
Alantra Partners
3.79%
-3.99%
-23.83%
★★★★★☆
Flügger group
30.11%
1.55%
-29.23%
★★★★☆☆
Practic
5.21%
4.49%
7.23%
★★★★☆☆
Inversiones Doalca SOCIMI
15.57%
6.53%
7.16%
★★★★☆☆
Eurofins-Cerep
0.46%
6.80%
6.93%
★★★★☆☆
MCH Group
124.09%
12.40%
43.58%
★★★★☆☆
Click here to see the full list of 324 stocks from our European Undiscovered Gems With Strong Fundamentals screener.
We'll examine a selection from our screener results.
Simply Wall St Value Rating: ★★★★★★
Overview: Sonaecom SGPS operates globally in the technology, media, and telecommunications sectors with a market capitalization of €764.42 million.
Operations: Sonaecom generates revenue primarily from its media segment (€16.38 million) and technology sector (€3.02 million). The company's financial structure reflects a focus on these areas, with holding activities contributing €0.74 million to the overall revenue.
Sonaecom, SGPS, a nimble player in the telecom sector, has shown a robust earnings growth of 150% over the past year, outpacing the industry average of 16.8%. Despite a notable one-off loss of €19.3M impacting recent results, its debt-free status provides financial flexibility. With a price-to-earnings ratio at 10.6x compared to the Portuguese market's 11.8x, it seems attractively valued. Recent earnings showed sales at €1.66M and revenue at €4.15M for Q1 2025; however, net income dipped to €13.66M from last year's €25.48M, indicating potential challenges ahead despite its promising growth trajectory.
Click here to discover the nuances of Sonaecom SGPS with our detailed analytical health report.
Gain insights into Sonaecom SGPS' historical performance by reviewing our past performance report.
Simply Wall St Value Rating: ★★★★★★
Overview: engcon AB (publ) specializes in the design, production, and sale of excavator tools across various international markets, with a market cap of approximately SEK14.07 billion.
Operations: The company generates revenue primarily from the Construction Machinery & Equipment segment, amounting to SEK1.70 billion. It operates across multiple international markets, focusing on excavator tools.
Engcon, a dynamic player in the machinery sector, has seen its earnings soar by 21.5% over the past year, outpacing industry growth of 2.8%. Its debt to equity ratio impressively fell from 15.9% to just 4% over five years, underscoring financial prudence. With EBIT covering interest payments 12.9 times over and high-quality earnings reported, Engcon's financial health seems robust. Recent dividends of SEK 1 per share highlight shareholder value focus while sales rose to SEK 446 million in Q1 from SEK 394 million last year, reflecting solid operational performance amidst strategic market expansions and ongoing patent litigation resolution efforts.
Engcon's revenue growth is driven by Nordic market recovery and strategic expansion. Click here to explore the full narrative on Engcon's investment potential.
Simply Wall St Value Rating: ★★★★★☆
Overview: Cicor Technologies Ltd. is a global company that, along with its subsidiaries, focuses on the development and manufacturing of electronic components, devices, and systems, with a market capitalization of CHF 729.42 million.
Operations: Cicor Technologies generates revenue primarily from its Electronic Manufacturing Services (EMS) Division, which accounts for CHF 438.01 million, and the Advanced Substrates (AS) Division contributing CHF 45.31 million.
Cicor Technologies is carving a niche in the European aerospace and defense sectors, leveraging strategic acquisitions like Mercury's electronics site in Geneva. With a satisfactory net debt to equity ratio of 32.2%, the company has seen its earnings grow by 131.7% over the last year, outpacing industry averages. Cicor's price-to-earnings ratio of 26.8x remains competitive within its sector, while EBIT covers interest payments tenfold, showcasing financial robustness. Despite recent shareholder dilution and market volatility, Cicor's strategic moves position it well for future growth amidst geopolitical shifts and currency fluctuations impacting operations across Europe.
Cicor Technologies' strategic M&A and operational improvements enhance EBITDA margins significantly. Click here to explore the full narrative on Cicor Technologies.
Gain an insight into the universe of 324 European Undiscovered Gems With Strong Fundamentals by clicking here.
Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ENXTLS:SNC OM:ENGCON B and SWX:CICN.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Arsenal's ruthless Eze coup shows intent
Arsenal's dramatic move to steal Eberechi Eze away from arch-rivals Tottenham Hotspur is a ruthless statement of intent designed to show this is the season they plan to finally claim the biggest prizes. Spurs were ready to roll out the welcoming carpet for Crystal Palace's England forward on Wednesday, the deal virtually done with every indication the 27-year-old was set on the move. It then filtered out that Arsenal were assessing the seriousness of a knee injury to forward Kai Havertz, which could potentially put a dent in their attacking resources - a weakness that played a significant part in manager Mikel Arteta's side ending empty handed for the fifth year in succession last season. Instead of taking the cheaper option of exploring the loan market, as was first expected, Arsenal went for broke in spectacular style by setting up a £60m coup to take Eze to Emirates Stadium from right under the noses of Spurs. Eze's move to Arsenal, which is now fully expected to be successfully concluded, is not simply a devastating psychological blow aimed across north London at Spurs. It is a clear signal that they have no intention of falling short in their stated aim of mounting a serious Premier League title challenge, as well as making inroads deep into the Champions League once more after reaching the semi-final last season. It is strategy in stark contrast to the inertia that gripped Arsenal last season, when their failure to solve an obvious problem - namely sign a recognised striker - cost them dearly. Spurs thought they had Eze wrapped up, the possibility of a cash-plus-Richarlison deal discussed, but Arsenal moved with lightning speed once they were confronted by the possibility of Havertz facing a spell on the sidelines. Arsenal have been linked with Eze all summer, but it was thought their interest had cooled once Ethan Nwaneri agreed a new five-year contract, on top of signing Chelsea winger Noni Madueke in a £48.5m deal. Havertz's injury, and its potential consequences, reignited that interest to leave Spurs stunned. Arsenal move ahead of Spurs in race for £60m Eze Football Daily: Isak's social statement & who else is on the move? Arteta knows this is the season he must land a major prize, and to do this he has been heavily backed by Arsenal's hierarchy. As well as Madueke, the Gunners have concluded moves to sign Spain's outstanding midfield man Martin Zubimendi in a deal worth up to £60m and, at least 12 months too late, a recognised striker in Viktor Gyokeres, signed from Sporting Lisbon for £64m. In Eze, who had two years left on his Palace contract, Arsenal will get a versatile forward rich in natural talent who is a match-winner - as he proved when scoring the winner against Manchester City in the FA Cup final in May. This was a follow-up to the spectacular right-foot finish that set Palace on their way to a 3-0 win over Aston Villa at Wembley in the semi-final. Eze also scored the Eagles' opener when they beat Fulham 3-0 at Craven Cottage in the quarter-final. Eze has demonstrated he has the temperament and talent for the big occasion when inspiring Palace to the first major trophy in their history. Arsenal will hope he has plenty of those occasions ahead. He is a scorer and creator of goals, adding real threat to Arsenal's front line, with 14 goals in all competitions last season. Eze was a boyhood Arsenal fan and was part of the club's academy until he was 13. He may have been initially keen on a move to Spurs, but once the Gunners showed their hand was only one part of north London he was heading to. He has achieved his goals the hard way, spending time at Fulham, Reading and Millwall before signing for Queen's Park Rangers. He left Loftus Road for Palace in a £19.5m deal in August 2020. Spurs believe they did all they could to conclude a deal - apart from actually concluding it - but it is a hammer blow to chairman Daniel Levy and manager Thomas Frank, who also thought they had a deal for Morgan Gibbs-White in the bag only for him to sign a new contract at Nottingham Forest. Arsenal will revel in the local rivalry of snatching away a prime transfer target for Spurs, but the wider context demonstrates the Gunners are deadly serious about ending the wait for success that now stretches back to 2020. Eze has previously admitted to "crying for a week" when he was let go by Arsenal in 2011, but this gifted forward has now been given a golden opportunity to make up for lost time. Latest Arsenal news, analysis and fan views Ask about Arsenal - what do you want to know?
Yahoo
16 minutes ago
- Yahoo
Canadian North Resources Inc. Reports Operational and Financial Results for the Second Quarter Ended June 30, 2025
Highlights: Expanded bio-metallurgical programs from initial bio-leaching tests indicating metal extraction of 97.86-98.5% nickel and 96.9-97.7% cobalt, with the goal of achieving similarly high recoveries of copper and PGE metals from the Ferguson Lake Ni-Cu-Co PGE Project located in southeast Nunavut, Canada. Continued evaluation of multiple metal processing technologies to produce market-ready battery-grade nickel and cobalt compounds, copper and PGE metals from a low-cost, low-carbon footprint mine. Working with local governments and indigenous communities for permissions, permits and licenses to conduct environmental baselines studies; communicating with investors, and potential partners to support the future development of the Ferguson Lake Project. TORONTO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Canadian North Resources Inc. ('Canadian North' or the 'Company') (TSXV: CNRI; OTCQX: CNRSF; FSE: EO0 (E-O-zero)) is pleased to report its operational and financial results for the second quarter ended June 30, 2025. Dr. Kaihui Yang, President and CEO of the Company, commented: 'In the second quarter, we have expanded the bio-leaching tests to develop a mineral processing flowsheet for the high recovery of nickel, cobalt, copper and PGE for the Ferguson Lake Project. The new tests are focused on the recovery of copper and PGE, in additional to nickel and cobalt, following up the exceptional results of the bio-leaching amenability tests completed in 2024, which indicate very high extraction rates for nickel (97.8-98.9%) and cobalt (96.0-97.7%) plus encouraging initial extractions of Cu of 73.6 -75.4%. The results of the new tests are pending. When proven, this flowsheet can simplify mineral processing, bypassing smelting and metal refining, and it will substantially reduce the capital expenditures needed for mine development, energy consumption, and operating cost for production. We believe that bio-leach extraction is a promising technology for developing a low-cost, low-carbon footprint mine at the Ferguson Lake Project.' 'We have actively communicated with the governmental agencies and local communities for the permissions, permits and licenses to conduct environmental baselines studies, and we have increased our communications with investors for the potential mine development of the Ferguson Lake Project.' Quarter 2 of 2025 Highlights: The Company also engaged in the following activities in the second quarter: During the second Quarter, the Company's team communicated with local governments and communities for the permissions, permits and licenses to start the environmental baseline studies at the Ferguson Lake Project. The Management has increased communications with shareholders, investors and potential strategic partners for the further development of the Company and its Ferguson Lake Project. On April 15, 2025, the Company filed its operational and financial results for the fiscal year 2024. During the year, it also publicly disclosed an updated NI 43-101 Mineral Resource Estimate for the Ferguson Lake Project, confirming it as one of the largest and highest-grade copper-nickel-cobalt-PGE deposits in North America. In addition, the Company initiated bio-leaching tests, which achieved 96–98% extraction rates for nickel and cobalt, supporting the potential use of this technology in developing a low-carbon, environmentally sustainable mining operation at Ferguson Lake. On April 16, 2025, the Company filed with the TSX Venture Exchange ('TSXV') an update on its Normal Course Issuer Bid ('NCIB') that was announced on April 5, 2024. During the past year (from April 5, 2024, to April 4, 2025), the Company has repurchased a total of 202,300 Common Shares at an average price of $0.98 per share under the NCIB. The completion of this repurchase underscores the Management's commitment to returning value to shareholders while optimizing the Company's capital structure. On April 24, 2025, the Company announced that it has filed with the TSX Venture Exchange ('TSXV') a Notice of Intention to Make a Normal Course Issuer Bid which is proposed to commence on April 28, 2025 and terminate on April 27, 2026 or the earlier of the date all shares which are subject to the Normal Course Issuer Bid are purchased. The Company believes that the current market price does not fully represent the intrinsic value of CNRI's Common Shares. On May 27, 2025, the Company filed the interim operational and financial results of the first Quarter, 2025. During the first Quarter, the Company continued evaluation of multiple metal processing technologies to produce market-ready battery-grade nickel and cobalt compounds, copper and PGE metals from a low-cost, low-carbon footprint mine for the Ferguson Lake Ni-Cu-Co-PGE Project. The Company commenced follow-up extensive bio-metallurgical programs from initial bio-leaching tests indicating metal extraction of 97.86-98.5% nickel and 96.9-97.7% cobalt, with the goal of achieving similarly high recoveries of copper and PGE metals. The Company enhanced engagement with local governments, Indigenous communities, investors, and potential partners to support the future development of the Ferguson Lake Project. In Quarter 2, 2025, the Company expanded the bioleaching tests with RPC for the high recovery of copper and PGE in addition to nickel and cobalt, and continued the flotation tests with SGS for the Ferguson Lake project. The technical team has also prepared for the field working programs upon receiving the permissions and permits from the governmental agencies. On June 21, 2025, the Company announced the voting results for the election of its Board of Directors at its Annual and Special Meeting of Shareholders held on June 19, 2025. For the quarter ended June 30, 2025, The Company ended the quarter with cash and cash equivalents of $143,233 and reported a net loss and comprehensive loss of $292,890 or $0.00 per share. For the quarter end Financial Statement and Management's Discussion and Analysis, please see the Company website at or on SEDAR. Qualified Person: Dr. Trevor Boyd, and Technical Advisor for Canadian North Resources, a qualified person as defined by Canadian National Instrument 43-101 standards, has reviewed the technical content of this news release and has approved its dissemination. About Canadian North Resources Inc. Canadian North Resources Inc. is an exploration and development company focusing on the critical metals for the clean-energy, electric vehicles, battery and high-tech industries. The company is advancing its 100% owned Ferguson Lake nickel, copper, cobalt, palladium, and platinum project in the Kivalliq Region of Nunavut, Canada. The Ferguson Lake mining property contains a substantial National Instrument 43-101 compliant Mineral Resource Estimate announced on March 19 2024, which include Indicated Mineral Resources of 66.1 million tonnes (Mt) containing 1,093 million pounds (Mlb) copper at 0.75%, 678Mlb nickel at 0.47%, 79.3Mlb cobalt at 0.05%, 2.34 million ounces (Moz) palladium at 1.10gpt and 0.419Moz platinum at 0.19gpt; and Inferred Mineral Resources of 25.9Mt containing 558Mlb copper at 0.98%, 333Mlb nickel at 0.58%, 39.6Mlb cobalt at 0.07%, 1.192Moz palladium at 1.43gpt and 0.205Moz platinum at 0.25gpt. In particular, 80% of the Indicated Mineral Resources is Open Pit with 52.7Mt at 0.65% copper, 0.43% nickel, 0.05% cobalt, 0.97gpt palladium and 0.17gpt platinum, which provides a solid Mineral Resource base for the initial development of a potential large mine. The Mineral Resource model indicates significant potential for resource expansion along strike and at depth over the 15 km long mineralized belt and a number of undefined mineralization zones and prospective areas. (Refer to 'Independent Technical Report on the Mineral Resource Estimate for the Ferguson Lake Project, Nunavut, Canada ('the Technical Report')', prepared by SRK Consulting and Ronacher McKenzie Geoscience Inc., effective March 19, 2024, filed by the Company to SEDAR at on May 3, 2024. The Technical Report has also been posted on the Company's website at Qualified Person: Dr. Trevor Boyd, and Technical Advisor for Canadian North Resources, a qualified person as defined by Canadian National Instrument 43-101 standards has reviewed the technical content of this news release and has approved its dissemination. Further information please visit the website at or contact: Dr. Kaihui Yang, President and CEOPhone: 905-696-8288 (Canada)1-888-688-8809 (Toll-Free)Email: info@ Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking Statements Certain statements contained in this news release, including statements which may contain words such as 'expects', 'anticipates', 'intends', 'plans', 'believes', 'estimates', or similar expressions, and statements related to matters which are not historical facts, are forward-looking information within the meaning of applicable securities laws. Such forward-looking statements, which reflect management's expectations regarding the Company's future growth, results of operations, performance, business prospects and opportunities, are based on certain factors and assumptions and involve known and unknown risks and uncertainties which may cause the actual results, performance, or achievements to be materially different from future results, performance, or achievements expressed or implied by such forward-looking statements. These factors should be considered carefully, and readers should not place undue reliance on the Company's forward-looking statements. The Company believes that the expectations reflected in the forward-looking statements contained in this news release and the documents incorporated by reference herein are reasonable, but no assurance can be given that these expectations will prove to be correct. In addition, although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. The Company undertakes no obligation to release publicly any future revisions to forward-looking statements to reflect events or circumstances after the date of this news or to reflect the occurrence of unanticipated events, except as expressly required by law.
Yahoo
16 minutes ago
- Yahoo
Basilea Pharmaceutica Ltd (BPMUF) (H1 2025) Earnings Call Highlights: Strong Revenue Growth and ...
This article first appeared on GuruFocus. Global In-Market Sales Increase: Procemba sales increased by 24.8% for the 12-month period ending March 2025. Royalty Income Growth: 21.7% year-on-year increase in royalty income. Operating Result: Positive operating result of CHF 24 million for the first six months of 2025. Additional Funding: Secured $39 million in non-dilutive funding from BAA. Revenue: Total revenue of CHF 104 million, a 36% increase compared to the first half of 2024. Operating Expenses: CHF 55.7 million, mainly due to costs associated with the ongoing phase 3 program. Net Profit: CHF 15.8 million, compared to CHF 20.7 million in the first half of 2024. Net Cash Position: Positive net cash position of CHF 50.7 million as of June 30, 2025. Operating Cash Flow: Positive cash flow of CHF 23.1 million from operating activities. Debt Reduction: Reduced total debt by CHF 138.3 million from 2022 through June 30, 2025. Full Year 2025 Guidance: Total revenue expected to increase by about 8% to CHF 225 million. R&D Expenses: Projected to rise to CHF 105 million for 2025. Operating Profit Guidance: Expected operating profit of approximately CHF 50 million for 2025. Warning! GuruFocus has detected 5 Warning Signs with BPMUF. Is BPMUF fairly valued? Test your thesis with our free DCF calculator. Release Date: August 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Basilea Pharmaceutica Ltd (BPMUF) reported a strong financial performance for the first half of 2025, with a positive operating result of CHF 24 million. The company's leading commercial product, Procemba, saw a 24.8% increase in global in-market sales, contributing to a 21.7% year-on-year increase in royalty income. Basilea secured an additional $39 million in non-dilutive funding from BAA to support the development of its antifungal candidates. The company successfully launched its antibiotic Zayra in the US through a partnership with Innoviva Specialty Therapeutics. Basilea expanded its portfolio by in-licensing ceftibutin deaborbactam, a phase 3 ready novel oral antibiotic for complicated urinary tract infections. Negative Points The net profit for the first half of 2025 decreased to CHF 15.8 million from CHF 20.7 million in the first half of 2024, due to a one-time income tax benefit in the previous year. The company anticipates a 17% reduction in product revenue to about CHF 48 million year-on-year due to a decrease in product supply to Pfizer. R&D expenses are projected to rise to CHF 105 million, driven by the in-licensing transaction and associated costs. The phase 3 program for the newly in-licensed antibiotic is expected to start in approximately 18 months, which may delay potential revenue contributions. Currency fluctuations, particularly the devaluation of the US dollar against the Swiss franc, impacted financial results. Q & A Highlights Q: Why is there an 18-month delay before starting the phase 3 trial for the newly in-licensed antibiotic? Does this relate to securing additional funding? A: David Veitch, CEO, clarified that the delay is not due to funding issues. The 18-month period is necessary for regulatory interactions with health authorities and operational setup. Marc Engelhardt, CMO, added that the studies require a large patient supply, which takes time to prepare. Q: How does the expanded access program for fosmanogepix impact regulatory approval, given the large number of patients involved? A: Marc Engelhardt, CMO, explained that the data from the expanded access program could serve as confirmatory evidence in an NDA filing, provided it meets FDA guidelines for completeness and context. Q: How does the new oral antibiotic fit into the treatment landscape for complicated UTIs, which is dominated by IV treatments? A: Marc Engelhardt, CMO, stated that the oral antibiotic will serve both as an initial empirical therapy and a step-down treatment from IV antibiotics, offering flexibility in hospital and outpatient settings. Q: Why is there expected softness in product revenues in the second half of the year? A: Adesh Kaul, CFO, explained that the fluctuation is due to product delivery schedules and initial supplies related to the US launch and other markets, rather than any underlying weakness. Q: What factors could accelerate enrollment in the fosmanogepix phase 3 program? A: Marc Engelhardt, CMO, mentioned that geographic analysis and increased sponsor engagement at underperforming sites could enhance enrollment rates. Q: Can you provide details on the sales and marketing infrastructure for Zevtera's US rollout? A: David Veitch, CEO, highlighted that Innoviva Specialty Therapeutics has extensive experience in launching antibiotics, with a comprehensive US coverage including sales, medical affairs, and access teams. Q: How does the oral antibiotic compare to GSK's oral carbapenem in clinical development for complicated UTIs? A: Marc Engelhardt, CMO, noted that while there are similarities in trial design, the new antibiotic offers advantages in spectrum and dosing frequency, potentially capturing significant market share. Q: How is Crescemba performing in the APAC region, and how will it mitigate the impact of the 2027 loss of exclusivity? A: Adesh Kaul, CFO, reported strong growth in APAC, particularly in Japan, where exclusivity extends beyond 2027, contributing to sustained revenue despite upcoming patent expirations. For the complete transcript of the earnings call, please refer to the full earnings call transcript. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data